Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.31 |
| ▸ | CCR2 | P41597 | 1/20 | 0.30 |
| ▸ | FDPS | P14324 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | DHFR | P00374 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26785281 | 0.79 | SLC6A3 (0.33) | SLC6A3SLC6A2SLC6A4DHFR | |
| SCHEMBL23871088 | 0.78 | SLC6A3 (0.34) | SLC6A3SLC6A2SLC6A4DHFR | |
| SCHEMBL8283621 | 0.77 | CCR2 (0.33) | SLC6A3CCR2FDPSSLC6A2SLC6A4 | |
| SCHEMBL8471413 | 0.77 | CCR2 (0.33) | SLC6A3CCR2FDPSSLC6A2SLC6A4 | |
| SCHEMBL27601910 | 0.76 | EPHX1 (0.36) | SLC6A3CCR2FDPSSLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL9698143 | 0.75 | KDM4E (0.34) | SLC6A3CCR2FDPSSLC6A2SLC6A4 | |
| SCHEMBL16297547 | 0.74 | KDM4E (0.31) | — | |
| SCHEMBL12919161 | 0.72 | EPHX1 (0.35) | — | |
| SCHEMBL8010291 | 0.71 | TDP1 (0.33) | FDPS | |
| SCHEMBL6879318 | 0.71 | KDM4E (0.36) | SLC6A3CCR2FDPSSLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7301022-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2007-11-27 | — | — | US | disclosed |
| WO-2006089311-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2006-08-24 | — | — | WO | disclosed |
| US-20060183745-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183745-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | SLC6A3 1076/4885CCR2 1444/4885FDPS 2868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.